SAN DIEGO, CA—Emerging evidence is creating a fuller picture of the safety of pulsed-field ablation (PFA) for atrial fibrillation (AF), bringing into focus a risk profile that differs from other ...
HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback